CORT Q3 2025 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$208M+13.7% YoY

Gross Profit

$203M97.8% margin

Operating Income

$10M4.9% margin

Net Income

$19M9.3% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$54M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$824M

Total Liabilities

$192M

Stockholders' Equity

$632M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$208M	$183M	+13.7%
Gross Profit	$203M	$180M	+13.0%
Operating Income	$10M	$47M	-78.1%
Net Income	$19M	$47M	-58.5%